[Click eStock] "Celltrion Delivers Q2 Earnings Surprise... Poised for Strong Growth This Year"
DS Investment & Securities: "Celltrion Named Top Large-Cap Pick"
On July 29, DS Investment & Securities maintained its 'Buy' rating and set a target price of 320,000 won for Celltrion, naming it its top large-cap pick.
Minjung Kim, a researcher at DS Investment & Securities, stated, "Celltrion is expected to achieve strong earnings growth this year, led by new biosimilar products such as Omniclo, Aptozma, Stoboclo, and Ocenbelt."
Kim explained, "While Zympentra sales growth slowed somewhat in the second quarter, this was a temporary effect due to a concentration of rebate claims by insurers. Annual sales of 25.32 billion won should be attainable. In the second half, sales negotiations with Pfizer over Remsima IV and Zympentra are expected to be finalized, which could further drive marketing effectiveness."
Celltrion’s sales in the second quarter of this year were 1.3937 trillion won, up 45.1% from the same period last year. Operating profit rose 86.3% to 451.8 billion won, both figures exceeding market expectations of 1.2441 trillion won in sales and 400.7 billion won in operating profit.
In particular, Omniclo—the Zolair biosimilar that entered the European market as a first mover—soared from 71.7 billion won in first quarter sales to 116.7 billion won in the second quarter. Kim noted, "Omniclo is strengthening its dominance in the European market, which lacks competing products, and this year is expected to capture a market share of around 21%. Launching the high-dose 300mg version in the second half is projected to further expand its penetration in urticaria indications."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
This year, Celltrion's projected annual sales and operating profit have been revised upward by 5.5% and 8.1% to 5.6921 trillion won and 1.9453 trillion won, respectively. The strong growth of new pipelines such as Omniclo and Aptozma underpins this forecast. Kim stated, "This year marks the start of rapid growth in second-generation biosimilar sales, and we expect an acceleration in Celltrion's performance."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.